Hematology

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. B-Cell Chronic Lymphocytic Leukemia 48%
3. Survival 48%
4. Immunoglobulin Light-chain Amyloidosis 39%
5. Primary Myelofibrosis 38%
6. Amyloidosis 37%
7. Therapeutics 35%
8. Non-Hodgkin's Lymphoma 31%
9. Neoplasms 30%
10. Stem Cell Transplantation 27%
11. Lenalidomide 26%
12. Lymphoma 26%
13. Bone Marrow 25%
14. Waldenstrom Macroglobulinemia 24%
15. Plasma Cells 24%
16. Transplants 23%
17. Lymphoma, Large B-Cell, Diffuse 23%
18. Rituximab 21%
19. Mutation 21%
20. Polycythemia Vera 21%
21. Essential Thrombocythemia 20%
22. Acute Myeloid Leukemia 19%
23. Monoclonal Gammopathy of Undetermined Significance 19%
24. B-Lymphocytes 19%
25. T-Lymphocytes 18%
26. Progression-Free Survival 18%
27. Light 17%
28. Dexamethasone 17%
29. Hodgkin Disease 17%
30. B-Cell Lymphoma 16%
31. Drug Therapy 16%
32. Bortezomib 16%
33. Myelodysplastic Syndromes 15%
34. Cell Transplantation 14%
35. Chimeric Antigen Receptors 14%
36. Stem Cells 13%
37. Melanoma 13%
38. Cytogenetics 13%
39. Leukemia 13%
40. Recurrence 13%
41. Hematopoietic Stem Cell Transplantation 12%
42. Paraproteinemias 12%
43. Clinical Trials 12%
44. Amyloid 11%
45. Smoldering Multiple Myeloma 11%
46. Precursor Cell Lymphoblastic Leukemia-Lymphoma 11%
47. Allogeneic Cells 11%
48. Follicular Lymphoma 11%
49. Thalidomide 11%
50. POEMS Syndrome 10%
51. Cyclophosphamide 10%
52. Hematologic Neoplasms 10%
53. Systemic Mastocytosis 10%
54. Leukemia, Myelomonocytic, Chronic 10%
55. Confidence Intervals 10%
56. Psychological Burnout 9%
57. Melphalan 9%
58. Risk Management 9%
59. Serum 9%
60. Proteins 9%
61. Hematopoietic Stem Cells 9%
62. Transplantation 8%
63. Population 8%
64. ibritumomab tiuxetan 8%
65. Amyloidosis, Hereditary, Transthyretin-Related 7%
66. Genes 7%
67. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7%
68. Mantle-Cell Lymphoma 7%
69. Lymphocytes 7%
70. Mortality 7%
71. ixazomib 7%
72. Myeloproliferative Disorders 7%
73. Pharmaceutical Preparations 7%
74. Immunotherapy 7%
75. Chromosome Aberrations 7%
76. Safety 7%
77. Graft vs Host Disease 7%
78. PCI 32765 7%
79. Lymphocytosis 7%
80. Immunoglobulin Light Chains 7%
81. Incidence 7%
82. Prednisone 7%
83. pomalidomide 7%
84. Biopsy 7%
85. Fluorescence In Situ Hybridization 7%
86. Kidney 7%
87. Biomarkers 6%
88. Cell- and Tissue-Based Therapy 6%
89. Anemia 6%
90. Immunoglobulin M 6%
91. Physicians 6%
92. Thrombocytosis 6%
93. Venous Thromboembolism 6%
94. Proteasome Inhibitors 6%
95. Disease Progression 6%
96. Lymphoproliferative Disorders 6%
97. Monocytes 6%
98. daratumumab 6%
99. Immunoglobulins 5%
100. Thrombosis 5%